NAM vs NR vs NMN: Which NAD Precursor Raises Blood NAD Levels Most
A completed Nestlé-sponsored trial directly compared three popular NAD precursors head-to-head in healthy adults.
Summary
NAD+ is a coenzyme essential to energy metabolism, DNA repair, and cellular aging. Millions of people supplement with NAD precursors — nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN) — hoping to boost NAD levels and slow aging. But until recently, direct head-to-head comparisons in humans were scarce. This completed clinical trial, sponsored by Nestlé's research division, enrolled healthy adults and measured whole blood NAD metabolome changes after supplementing with each of the three precursors. The goal was to determine which form most effectively raises circulating NAD levels. Results from this trial could help consumers and clinicians make more informed choices about which NAD precursor to use, at what dose, and whether cost differences between these compounds are justified by meaningful differences in biological effect.
Detailed Summary
NAD+ sits at the center of human metabolism, powering hundreds of enzymatic reactions involved in energy production, DNA repair, inflammation control, and sirtuin activation — pathways directly linked to aging and age-related disease. NAD+ levels decline with age, and restoring them has become a major target in longevity research. The supplement market has responded with multiple NAD precursor products, but rigorous human comparisons have been limited.
This completed clinical trial (NCT05517122), sponsored by Société des Produits Nestlé, enrolled healthy adult participants and administered three distinct oral NAD precursors: nicotinamide (NAM), nicotinamide riboside (NR), and nicotinamide mononucleotide (NMN). The primary outcome was change in the whole blood NAD metabolome — a comprehensive snapshot of NAD and its related metabolites, not just total NAD alone.
The full dataset has not been published in the available abstract, so specific comparative efficacy results cannot be reported here. However, the trial's completion and its comprehensive metabolomic outcome measure make it one of the more methodologically rigorous head-to-head human studies attempted for this class of supplements. Measuring the full NAD metabolome rather than a single biomarker provides a richer picture of how each precursor is processed and converted.
For clinicians and health-conscious consumers, the practical stakes are high. NMN and NR are significantly more expensive than NAM, yet preclinical data has not consistently demonstrated superiority. If NAM — the cheapest and most widely available precursor — proves equally or more effective at raising blood NAD, that would represent a major shift in supplementation guidance.
Caveats are significant: this summary is based on the abstract only, results have not been fully published, the sponsor has commercial interests in nutritional products, and the study was conducted in healthy adults, limiting generalizability to older or metabolically compromised populations.
Key Findings
- Trial directly compared NAM, NR, and NMN oral supplementation on whole blood NAD metabolome in healthy adults.
- Measuring the full NAD metabolome — not just NAD alone — captures how each precursor is converted and utilized differently.
- Study is now completed, making full publication of results an anticipated landmark for NAD supplement guidance.
- Nestlé sponsorship signals growing corporate investment in NAD biology and nutritional supplement science.
- Head-to-head human data could resolve whether premium-priced NR and NMN outperform inexpensive NAM.
Methodology
This is a completed interventional clinical trial (Phase NA) registered on ClinicalTrials.gov (NCT05517122), enrolling healthy adult participants across three oral NAD precursor arms: NAM, NR, and NMN. The primary endpoint was change in whole blood NAD metabolome, offering a comprehensive metabolite-level comparison rather than a single biomarker readout. Sponsor is Société des Produits Nestlé (SPN), a major food and nutrition research organization.
Study Limitations
This summary is based on the abstract only, as full results have not been published or made publicly available; key comparative efficacy data cannot be reported. Sponsor conflict of interest should be noted, as Nestlé has commercial interests in nutritional supplements. The trial enrolled healthy adults only, which may limit applicability to older individuals or those with metabolic disease where NAD decline is more pronounced.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.